blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1592449

EP1592449 - SENSITIZING CELLS FOR APOPTOSIS BY SELECTIVELY BLOCKING CYTOKINES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.04.2009
Database last updated on 06.07.2024
Most recent event   Tooltip30.09.2011Lapse of the patent in a contracting state
New state(s): CY, TR
published on 02.11.2011  [2011/44]
Applicant(s)For all designated states
Stassi, Giorgio, Dr.
Dipartimento di Discipline Chirurgiche ed Oncologiche, Laboratorio di Fisiopatologia Cellulare e Molecolare, Via del Vespro, 129
90127 Palermo / IT
For all designated states
Todaro, Matilde, Dr.
Dipartimento di Discipline Chirurgiche ed Oncologiche, Laboratorio di Fisiopatologia Cellulare e Molecolare, Via del Vespro, 129
90127 Palermo / IT
[2008/22]
Former [2005/45]For all designated states
Stassi, Giorgio, Dr.
Dipartimento di Discipline Chirurgiche ed Oncologiche, Laboratorio di Fisiopatologia Cellulare e Molecolare, Via del Vespro, 129
90127 Palermo / IT
For all designated states
Todaro, Matilde, Dr.
Dipartimento di Discipline Chirurgiche ed Oncologiche, Laboratorio di Fisiopatologia Cellulare e Molecolare, Via del Vespro, 129
90127 Palermo / IT
Inventor(s)01 / see applicant
...
 [2005/45]
Representative(s)Weiss, Wolfgang, et al
Weickmann & Weickmann
Patent- und Rechtsanwälte PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2006/21]Weiss, Wolfgang, et al
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Former [2006/18](deleted)
Former [2005/45]Huhn, Michael
Isenbruck Bösl Hörschler Wichmann Huhn Patentanwälte Theodor-Heuss-Anlage 12
68165 Mannheim / DE
Application number, filing date04709222.609.02.2004
[2005/45]
WO2004EP01177
Priority number, dateEP2003000260307.02.2003         Original published format: EP 03002603
[2005/45]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004069274
Date:19.08.2004
Language:EN
[2004/34]
Type: A2 Application without search report 
No.:EP1592449
Date:09.11.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 19.08.2004 takes the place of the publication of the European patent application.
[2005/45]
Type: B1 Patent specification 
No.:EP1592449
Date:28.05.2008
Language:EN
[2008/22]
Search report(s)International search report - published on:EP11.11.2004
ClassificationIPC:A61K45/00, A61K39/395, A61K45/06, A61P35/00
[2007/48]
CPC:
A61K45/06 (EP,US); A61K31/337 (EP,US); A61K31/704 (EP,US);
A61K31/7105 (EP,US); A61K31/713 (EP,US); A61K33/243 (EP,US);
A61K38/1793 (EP,US); A61K38/19 (EP,US); A61K38/191 (EP,US);
A61P1/00 (EP); A61P1/16 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P13/08 (EP); A61P13/12 (EP);
A61P15/00 (EP); A61P17/00 (EP); A61P19/00 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P27/02 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/06 (EP);
A61P7/00 (EP); A61K2039/505 (EP,US); Y02A50/30 (EP,US) (-)
C-Set:
A61K31/337, A61K2300/00 (EP,US);
A61K31/704, A61K2300/00 (US,EP);
A61K31/7105, A61K2300/00 (EP,US);
A61K31/713, A61K2300/00 (EP,US);
A61K33/24, A61K2300/00 (EP,US);
A61K38/1793, A61K2300/00 (US,EP);
A61K38/191, A61K2300/00 (US,EP);
A61K38/19, A61K2300/00 (US,EP)
(-)
Former IPC [2005/45]A61K45/00, A61K39/395, A61K45/06, A61P35/00, A61P37/06
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/45]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:SENSIBILISIERUNG VON ZELLEN FÜR DIE APOPTOSE DURCH SELEKTIVE BLOCKADE VON ZYTOKINEN[2005/45]
English:SENSITIZING CELLS FOR APOPTOSIS BY SELECTIVELY BLOCKING CYTOKINES[2005/45]
French:SENSIBILISATION DE CELLULES A L'APOPTOSE PAR BLOCAGE SELECTIF DE CYTOKINES[2007/52]
Former [2005/45]SENSIBILISATION DE CELLULES A L' APOPTOSE PAR BLOQUAGE SELECTIVE DE CYTOKINES
Entry into regional phase02.09.2005National basic fee paid 
02.09.2005Designation fee(s) paid 
02.09.2005Examination fee paid 
Examination procedure02.09.2005Amendment by applicant (claims and/or description)
02.09.2005Examination requested  [2005/45]
17.03.2006Despatch of a communication from the examining division (Time limit: M04)
01.09.2006Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
02.10.2006Reply to a communication from the examining division
08.10.2007Date of oral proceedings
23.11.2007Minutes of oral proceedings despatched
29.11.2007Communication of intention to grant the patent
08.04.2008Fee for grant paid
08.04.2008Fee for publishing/printing paid
Divisional application(s)EP08007399.2  / EP2075008
Opposition(s)03.03.2009No opposition filed within time limit [2009/19]
Request for further processing for:02.10.2006Request for further processing filed
02.10.2006Full payment received (date of receipt of payment)
Request granted
13.10.2006Decision despatched
Fees paidRenewal fee
27.02.2006Renewal fee patent year 03
30.11.2006Renewal fee patent year 04
30.11.2007Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY28.05.2008
CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
TR28.05.2008
BG28.08.2008
GR29.08.2008
PT28.10.2008
HU29.11.2008
LU09.02.2009
MC28.02.2009
[2011/43]
Former [2011/32]CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
BG28.08.2008
GR29.08.2008
PT28.10.2008
HU29.11.2008
LU09.02.2009
MC28.02.2009
Former [2011/21]CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
BG28.08.2008
GR29.08.2008
PT28.10.2008
LU09.02.2009
MC28.02.2009
Former [2010/50]CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
BG28.08.2008
GR29.08.2008
PT28.10.2008
MC28.02.2009
Former [2009/44]CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
BG28.08.2008
PT28.10.2008
MC28.02.2009
Former [2009/23]CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
BG28.08.2008
PT28.10.2008
Former [2009/22]CZ28.05.2008
EE28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
PT28.10.2008
Former [2009/14]CZ28.05.2008
FI28.05.2008
RO28.05.2008
SI28.05.2008
SK28.05.2008
PT28.10.2008
Former [2009/13]CZ28.05.2008
FI28.05.2008
SI28.05.2008
SK28.05.2008
PT28.10.2008
Former [2008/50]FI28.05.2008
SI28.05.2008
Former [2008/44]SI28.05.2008
Cited inInternational search[XY]WO8909621  (RITTER MARY ALICE [GB], et al) [X] 1-7,9-22,24,27-41 * example 7; claim -; table 3 * [Y] 8,23;
 [Y]WO0004901  (UNIV JEFFERSON [US]) [Y] 1-24,27-41 * page 5, line 15 - page 6, line 25; claims 44-54 *;
 [X]WO0204009  (IMMUNEX CORP [US], et al) [X] 1-24,27-41 * page 3, line 1 - line 37 * * page 4, line 1 - page 5, line 14 * * page 7, line 31 - page 19, line 21; claim - *;
 [XY]  - LU ZHAO YANG ET AL, "Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments.", BLOOD, (1995), vol. 86, no. 8, ISSN 0006-4971, pages 3123 - 3131, XP002247617 [X] 1-7,9-21,24,27,29-31,33,35,38-41 * page 3123, column 1, paragraph 1 - column 2, paragraph 1 * [Y] 8,22,23,28,32,34,36,37
 [XY]  - MAINOU-FOWLER T ET AL, "Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia.", LEUKEMIA & LYMPHOMA. SWITZERLAND MAY 1996, (199605), vol. 21, no. 5-6, ISSN 1042-8194, pages 369 - 377, XP009013850 [X] 1-12 * Abstract; page 370, column 2, paragraph 1 * * page 371, column 1, paragraph 3 * [Y] 13-24,27-41
 [Y]  - LOMO JON ET AL, "Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-xL and McL-1.", BLOOD, (1997), vol. 89, no. 12, ISSN 0006-4971, pages 4415 - 4424, XP002247618 [Y] 1-24,27-41 * Abstract *
 [Y]  - NING ZHI-QIANG ET AL, "Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: Role for inhibition of an early response gene, Berg36.", EUROPEAN JOURNAL OF IMMUNOLOGY, (1996), vol. 26, no. 10, ISSN 0014-2980, pages 2356 - 2363, XP009013662 [Y] 1-24,27-41 * Abstract; page 2356, column 2, line 17 - line 18 *

DOI:   http://dx.doi.org/10.1002/eji.1830261013
 [Y]  - STASSI GIORGIO ET AL, "Autoimmune thyroid disease: new models of cell death in autoimmunity.", NATURE REVIEWS. IMMUNOLOGY. ENGLAND MAR 2002, (200203), vol. 2, no. 3, ISSN 1474-1733, pages 195 - 204, XP009013434 [Y] 1-24,27-41 * page 202, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1038/nri750
 [A]  - OPPENHEIM JOOST J, "Cytokines: Past, present, and future.", INTERNATIONAL JOURNAL OF HEMATOLOGY, (200107), vol. 74, no. 1, ISSN 0925-5710, pages 3 - 8, XP009013664 [A] 1-24,27-41 * the whole document * * page 7, column 1, paragraph 2 *
 [PX]  - STASSI GIORGIO ET AL, "Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.", CANCER RESEARCH, (20031015), vol. 63, no. 20, ISSN 0008-5472, pages 6784 - 6790, XP002280883 [PX] 1-24,27-41 * the whole document *
 [Y]  - STASSI G ET AL, "CONTROL OF TARGET CELL SURVIVAL IN THYROID AUTOIMMUNITY BY T HELPER CYTOKINES VIA REGULATION OF APOPTOTIC PROTEINS", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, (200012), vol. 1, no. 6, ISSN 1529-2908, pages 483 - 488, XP009013425 [Y] 1-24,27-41 * Discussion (p. 487) *

DOI:   http://dx.doi.org/10.1038/82725
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.